Ascletis loses ITC ruling on ASC41 and ASC43F

Ascletis Pharma Inc. (HKEX:1672) announced the final judgment from the United States International Trade Commission (ITC) regarding its legal proceedings with Viking Therapeutics, Inc. The ruling, issued on May 29, 2025, imposes a seven-year prohibition on the importation of Ascletis's ASC41 and ASC43F drug candidates into the United States. Furthermore, Ascletis and its former counsel face joint liability for a payment of USD567,059.85 as a sanction related to procedural disputes.